People · Operator
Named in public records as an officer, director or promoter · active 2012–2023 · Biotechnology, Pharmaceuticals, Other Health Care, Other, Other Technology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avalyn Pharma Inc. | — | Biotechnology | Series D+ | $244.0M | $2.7B | 2023 |
| Aclaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $192.5M | $612.3M | 2012 |
| Rallybio Holdings, LLC | — | Other Health Care | Series D+ | $157.8M | $69.6M | 2020 |
| Ivenix, Inc. | — | Biotechnology | Series B | $82.9M | $396.9M | 2017 |
| ABK Biomedical Inc | — | Other | Series B | $80.7M | $11.5M | 2022 |
| NFlection Therapeutics, Inc. | — | Biotechnology | Series B | $44.0M | $43.6M | 2016 |
| INTELLEFLEX Corp | — | Other | Series A | $14.9M | $88.7M | 2012 |
| ShopWell Solutions, Inc. | — | Other Technology | Seed | $8.3M | $28.6M | 2012 |
| Redirect Health, LLC | — | Healthtech | Seed | $3.4M | $29.5M | 2021 |
| Rainmaker Holdings II, LLC | — | Lodging and Conventions | Pre-Seed | $145K | $1.0M | 2013 |
Ketan Patel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ketan Patel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher Powala | 2 | 3 |
| Ketan W. Patel | 2 | 2 |
| ROBERT SCHWARTZ | 1 | 21 |
| Corey Goodman | 1 | 13 |
| Jonathan Leff | 1 | 11 |
| Kush Parmar | 1 | 10 |
| Paul Johnson | 1 | 10 |
| Mark De Souza | 1 | 10 |
| Albert Cha | 1 | 9 |
| Tim Shannon | 1 | 9 |
| Tiba Aynechi | 1 | 9 |
| David Gordon | 1 | 8 |
| John Clarke | 1 | 8 |
| ANAND MEHRA | 1 | 7 |
| Robert Orr | 1 | 7 |
| Wei Li | 1 | 7 |
| Stephen Tullman | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| Peter Moldt | 1 | 6 |
| Brandon Hull | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.